nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2007 | Molecular Imaging

¹⁸F-labeled mini-PEG spacered RGD dimer (¹⁸F-FPRGD2): synthesis and microPET imaging of α_vβ₃ integrin expression

verfasst von: Zhanhong Wu, Zi-Bo Li, Weibo Cai, Lina He, Frederick T. Chin, Fang Li, Xiaoyuan Chen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We have previously reported that ¹⁸F-FB-E[c(RGDyK)]₂ (¹⁸F-FRGD2) allows quantitative PET imaging of integrin α_vβ₃ expression. However, the potential clinical translation was hampered by the relatively low radiochemical yield. The goal of this study was to improve the radiolabeling yield, without compromising the tumor targeting efficiency and in vivo kinetics, by incorporating a hydrophilic bifunctional mini-PEG spacer.

Methods

¹⁸F-FB-mini-PEG-E[c(RGDyK)]₂ (¹⁸F-FPRGD2) was synthesized by coupling N-succinimidyl-4-¹⁸F-fluorobenzoate (¹⁸F-SFB) with NH₂-mini-PEG-E[c(RGDyK)]₂ (denoted as PRGD2). In vitro receptor binding affinity, metabolic stability, and integrin α_vβ₃ specificity of the new tracer ¹⁸F-FPRGD2 were assessed. The diagnostic value of ¹⁸F-FPRGD2 was evaluated in subcutaneous U87MG glioblastoma xenografted mice and in c-neu transgenic mice by quantitative microPET imaging studies.

Results

The decay-corrected radiochemical yield based on ¹⁸F-SFB was more than 60% with radiochemical purity of >99%. ¹⁸F-FPRGD2 had high receptor binding affinity, metabolic stability, and integrin α_vβ₃-specific tumor uptake in the U87MG glioma xenograft model comparable to those of ¹⁸F-FRGD2. The kidney uptake was appreciably lower for ¹⁸F-FPRGD2 compared with ¹⁸F-FRGD2 [2.0 ± 0.2%ID/g for ¹⁸F-FPRGD2 vs 3.0 ± 0.2%ID/g for ¹⁸F-FRGD2 at 1 h post injection (p.i.)]. The uptake in all the other organs except the urinary bladder was at background level. ¹⁸F-FPRGD2 also exhibited excellent tumor uptake in c-neu oncomice (3.6 ± 0.1%ID/g at 30 min p.i.).

Conclusion

Incorporation of a mini-PEG spacer significantly improved the overall radiolabeling yield of ¹⁸F-FPRGD2. ¹⁸F-FPRGD2 also had reduced renal uptake and similar tumor targeting efficacy as compared with ¹⁸F-FRGD2. Further testing and clinical translation of ¹⁸F-FPRGD2 are warranted.

Nur mit Berechtigung zugänglich

Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673–87.PubMedCrossRef

Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin α_vβ₃ antagonism. Anti-Cancer Agents Med Chem 2006;6:407–28.

Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin α_vβ₃ for angiogenesis. Science 1994;264:569–71.PubMedCrossRef

Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91–100.PubMedCrossRef

Haubner R, Wester H-J, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of α_vβ₃ integrin expression using ¹⁸F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781–5.PubMed

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated α_vβ₃ integrin in cancer patients by positron emission tomography and [¹⁸F]galacto-RGD. PLoS Med 2005;2:e70.PubMedCrossRef

Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, et al. Tumor targeting with radiolabeled α_vβ₃ integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146–51.PubMed

Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, et al. Integrin α_vβ₃-targeted imaging of lung cancer. Neoplasia 2005;7:271–9.PubMedCrossRef

Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS. Micro-PET imaging of α_vβ₃-integrin expression with ¹⁸F-labeled dimeric RGD peptide. Mol Imaging 2004;3:96–104.PubMedCrossRef

10.

Zhang X, Xiong Z, Wu X, Cai W, Tseng JR, Gambhir SS, et al. Quantitative PET imaging of tumor integrin α_vβ₃ expression with ¹⁸F-FRGD2. J Nucl Med 2006;47:113–21.PubMed

11.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. MicroPET imaging of glioma α_v-integrin expression using ⁶⁴Cu-labeled tetrameric RGD eptide. J Nucl Med 2005;46:1707–18.PubMed

12.

Cai W, Gambhir SS, Chen X. Multimodality tumor imaging targeting integrin α_vβ₃. Biotechniques 2005;39:S6–17.CrossRef

13.

Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive ¹⁸F-labeling agent, N-[2-(4-¹⁸F-fluorobenzamido)ethyl]maleimide (¹⁸F-FBEM), and the synthesis of RGD peptide-based tracer for PET imaging of α_vβ₃ integrin expression. J Nucl Med 2006;47:1172–80.PubMed

14.

Haubner R. α_vβ₃-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006;33 Suppl 11:54–63.PubMedCrossRef

15.

Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin α_vβ₃ targeted radiotracers for tumor imaging. Mol Pharm 2006;3:472–87.PubMedCrossRef

16.

Ye Y, Bloch S, Xu B, Achilefu S. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem 2006;49:2268–75.PubMedCrossRef

17.

Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 2003;9:2717–25.PubMedCrossRef

18.

Watson N, Duncan G, Annan WS, van der Walle CF. A tetravalent RGD ligand for integrin-mediated cell adhesion. J Pharm Pharmacol 2006;58:959–66.PubMedCrossRef

19.

Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med 2005;46:1940–5.PubMed

20.

Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214–21.PubMedCrossRef

21.

Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, et al. MicroPET imaging of brain tumor angiogenesis with ¹⁸F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004;31:1081–9.PubMedCrossRef

22.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. Pegylated Arg-Gly-Asp peptide: ⁶⁴Cu labeling and PET imaging of brain tumor α_vβ₃-integrin expression. J Nucl Med 2004;45:1776–83.PubMed

23.

Cai W, Olafsen T, Zhang X, Cao Q, Gambhir SS, Williams LE, et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an ¹⁸F-labeled T84.66 anti–carcinoembryonic antigen diabody. J Nucl Med 2007;48:304–10.PubMed

24.

Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006;47:2048–56.PubMed

25.

Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of ⁶⁴Cu-labeled Abegrin™, a humanized monoclonal antibody against integrin α_vβ₃. Cancer Res 2006;66:9673–81.PubMedCrossRef

26.

Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105–15.PubMedCrossRef

27.

Harris TD, Kalogeropoulos S, Nguyen T, Dwyer G, Edwards DS, Liu S, et al. Structure-activity relationships of ¹¹¹In- and ^99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. Bioconjug Chem 2006;17:1294–313.PubMedCrossRef

28.

Onthank DC, Liu S, Silva PJ, Barrett JA, Harris TD, Robinson SP, et al. ⁹⁰Y and ¹¹¹In complexes of a DOTA-conjugated integrin α_vβ₃ receptor antagonist: different but biologically equivalent. Bioconjug Chem 2004;15:235–41.PubMedCrossRef

29.

Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, et al. Design, synthesis, and evaluation of radiolabeled integrin α_vβ₃ receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003;18:627–41.PubMedCrossRef

30.

Mousa SA, Mohamed S, Wexler EJ, Kerr JS. Antiangiogenesis and anticancer efficacy of TA138, a novel α_vβ₃ antagonist. Anticancer Res 2005;25:197–206.PubMed

31.

Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH, et al. ¹⁸F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004;31:179–89.PubMedCrossRef

32.

Boturyn D, Coll JL, Garanger E, Favrot MC, Dumy P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc 2004;126:5730–9.PubMedCrossRef

33.

Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: ¹⁸F-labeled RGD and octreotide analogs. J Nucl Med 2004;45:892–902.PubMed

34.

Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, et al. First ¹⁸F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004;10:3593–606.PubMedCrossRef

35.

Kilbourn MR, Dence CS, Welch MJ, Mathias CJ. Fluorine-18 labeling of proteins. J Nucl Med 1987;28:462–70.PubMed

36.

Wester HJ, Hamacher K, Stoecklin G. A comparative study of n.c.a. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996;23:365–72.PubMedCrossRef

37.

Wilbur DS. Radiohalogenation of proteins: an overview of radionuclides, labeling methods and reagents for conjugate labeling. Bioconjug Chem 1992;3:432–70.CrossRef

38.

Marik J, Sutcliffe JL. Click for PET: rapid preparation of [¹⁸F]fluoropeptides using CuI catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett 2006;47:6681–4.CrossRef

39.

Lee CC, Sui G, Elizarov A, Shu CJ, Shin YS, Dooley AN, et al. Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science 2005;310:1793–6.PubMedCrossRef

40.

Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate ^99mTc-NC100692. J Nucl Med 2006;47:1434–9.PubMed

Titel: 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of αvβ3 integrin expression
verfasst von: Zhanhong Wu
Zi-Bo Li
Weibo Cai
Lina He
Frederick T. Chin
Fang Li
Xiaoyuan Chen
Publikationsdatum: 01.11.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0427-0

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule

Paediatric doses—a critical appraisal of the EANM paediatric dosage card

Comparison of 99mTc-annexin A5 with 18F-FDG for the detection of atherosclerosis in ApoE−/− mice

Quantification of myocardial blood flow with 82Rb dynamic PET imaging

EANM Marie Curie training grant project report PET–CT in oncology imaging